The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.

Background: Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy.

Methods: Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries.

The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.

Background And Aims: Fatty liver disease is highly prevalent, resulting in overarching wellbeing and economic costs. Addressing it requires comprehensive and coordinated multisectoral action. We developed a fatty liver disease Sustainable Development Goal (SDG) country score to provide insights into country-level preparedness to address fatty liver disease through a whole-of-society lens.

A global action agenda for turning the tide on fatty liver disease.

Background And Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care.

Approach And Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice.

A global research priority agenda to advance public health responses to fatty liver disease.

Background & Aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community.

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas.

Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD policies, guidelines, civil society engagement, clinical management, and epidemiologic data.

A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.

Background: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition that requires a comprehensive and coordinated response across sectors and disciplines.

Aims: In the absence of a multisectoral framework to tackle this condition, we developed one using the sustainable development goals (SDGs) as the basis for converging thinking about the design and delivery of public health responses.

Methods: A multidisciplinary group identified the SDG targets and indicators for inclusion in the new framework through a two-stage process.

NAFLD: Challenges and opportunities to address the public health problem in Latin America.

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions worldwide. Collectively, Latin American countries have some of the highest obesity rates in the world and the fastest-growing prevalence of type 2 diabetes mellitus (T2DM). Since obesity and T2DM are intrinsically linked with NAFLD, epidemiological projections are worrisome.

Malnutrition: the silent pandemic.

Healthy diets are a human right and the foundation of just, resilient societies

Demarcating geographic regions using community detection in commuting networks with significant self-loops.

We develop a method to identify statistically significant communities in a weighted network with a high proportion of self-looping weights. We use this method to find overlapping agglomerations of U.S.

Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the F-AV-1451 Tracer for Tau Imaging.

The F-AV-1451 PET tracer binds to tau, an Alzheimer's disease biomarker. The standardized uptake value ratio (SUVR) 80-100 min window is widely used to quantify tau binding, although F-AV-1451 continues increasing relative to a reference region in regions with tau deposition. Left uncorrected, acquisition time inaccuracies can lead to errors from -4% to 6% in 20-min SUVR measurements in subjects with Alzheimer's disease.

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

Unlabelled: The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligand F-AV-1451 in cognitively healthy control (HC) and Alzheimer disease (AD) subjects, using reference region analyses.

Methods: F-AV-1451 PET imaging was performed on 43 subjects (5 young HCs, 23 older HCs, and 15 AD subjects). Data were collected from 0 to 150 min after injection, with a break from 100 to 120 min.

[Treatment of hyperemesis gravidarum by electrostimulation of the vestibular apparatus].

26 patients hospitalized with Hyperemesis Gravidarum were treated with electrical stimulation of the vestibular system, as the symptoms of Hyperemesis Gravidarum resemble the symptoms of motion sickness, where the electrical stimulation has been used successfully. The patients were treated for one hour daily, two hours before the standard infusion therapy. 89% reported a decrease in vomiting and nausea during the first application, 85% a lasting improvement.